These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 11977454)

  • 41. Coming: a review of second-generation nonsteroidal anti-inflammatory drugs.
    Housholder GT; Chan JT
    J Gt Houst Dent Soc; 1997 Mar; 68(8):13-6. PubMed ID: 9594801
    [No Abstract]   [Full Text] [Related]  

  • 42. [Tolerable pain therapy in rheumatism saves long-term costs. Despite this most COX-2 candidates receive conventional NSAID therapy].
    MMW Fortschr Med; 2003 Jul; 145(29-30):61. PubMed ID: 12958786
    [No Abstract]   [Full Text] [Related]  

  • 43. Getting a grip on pain. A new drug may revolutionize arthritis care.
    Cowley G
    Newsweek; 1998 Dec; 132(24):66. PubMed ID: 10338868
    [No Abstract]   [Full Text] [Related]  

  • 44. COX-2 inhibitors.
    Crowther CL
    Lippincotts Prim Care Pract; 1999; 3(4):394-6. PubMed ID: 10624270
    [No Abstract]   [Full Text] [Related]  

  • 45. New reports on dental analgesics. NSAIDs and cardiovascular effects, celecoxib for dental pain, and a new analgesic--tramadol with acetaminophen.
    Wynn RL
    Gen Dent; 2002; 50(3):218-20, 22. PubMed ID: 12116507
    [No Abstract]   [Full Text] [Related]  

  • 46. [Cyclooxygenase 2 inhibitors and lung carcinoma].
    Spano JP; Chouahnia K; Morère JF
    Bull Cancer; 2004 May; 91 Suppl 2():S109-12. PubMed ID: 15899634
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The use of non-steroidal anti inflammatory drugs (NSAIDs)--COX-2 inhibitors].
    Tishler M; Langevetiz P; Nesher G
    Harefuah; 2002 Oct; 141(10):920-1. PubMed ID: 12420601
    [No Abstract]   [Full Text] [Related]  

  • 48. [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects].
    Burdan F; Korobowicz A
    Pol Merkur Lekarski; 2003 Apr; 14(82):352-5. PubMed ID: 12868201
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Analgesic effects of cyclooxygenase 2 inhibitors].
    Jayr C
    Bull Cancer; 2004 May; 91 Spec No():S125-31. PubMed ID: 15239341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HMO drug formulary access increases for COX-2s.
    Manag Care; 2002 Oct; 11(10):48. PubMed ID: 12415909
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cutting-edge pharmacotherapeutics.
    Mege J
    Pa Med; 1998 Dec; 101(12):17, 22. PubMed ID: 9883028
    [No Abstract]   [Full Text] [Related]  

  • 53. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
    Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
    [No Abstract]   [Full Text] [Related]  

  • 55. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
    Hochberg MC
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S502-17. PubMed ID: 12458820
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Arthritis drug approved for polyp prevention blazes trail for other prevention trials.
    Smigel K
    J Natl Cancer Inst; 2000 Feb; 92(4):297-9. PubMed ID: 10675374
    [No Abstract]   [Full Text] [Related]  

  • 57. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclooxygenase 2 selective agents and upper gastrointestinal disease.
    Palmer RH
    JAMA; 2000 Apr; 283(15):1961-2. PubMed ID: 10789662
    [No Abstract]   [Full Text] [Related]  

  • 59. Cyclooxygenase 2 selective agents and upper gastrointestinal disease.
    Fernandez H; Lesser GT
    JAMA; 2000 Apr; 283(15):1961; author reply 1962. PubMed ID: 10789661
    [No Abstract]   [Full Text] [Related]  

  • 60. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors.
    Stephens J; Laskin B; Pashos C; Peña B; Wong J
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii40-52. PubMed ID: 14585917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.